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Background: There are numerous reports describing the efficacy of fenofibrate in combination with ezetimibe for
treating dyslipidemia. In contrast, a study combining bezafibrate and ezetimibe has not yet been conducted. In this
study, we examined the safety, including the risk of gallstone formation, and the efficacy of long-term combination
therapy with bezafibrate and ezetimibe for treating dyslipidemia.
Methods: Dyslipidemic patients treated with 400 mg/day bezafibrate in combination with 10 mg/day ezetimibe for
the first time were eligible. We selected 157 institutions in Japan and conducted a 12-month prospective
observational study, with patients enrolled on the day they started combination therapy. Safety of the combination
was examined in terms of the type, onset, and severity of adverse drug reactions (ADRs). Efficacy was evaluated in
terms of the changes in low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C),
triglyceride (TG), and non-HDL cholesterol (non-HDL-C) levels from the start of combination therapy (baseline) to
the last observation carried forward (LOCF). Lipid levels were assessed at 1, 3, 6, and 12 months after starting
combination therapy.
Results: We enrolled 665 patients in this observational study. Safety was evaluated in 659, and ADRs occurred in 42
patients (6.4%). The most frequent ADRs were blood creatine phosphokinase increase (1.5%) and myalgia (0.8%).
Asymptomatic gallstones were observed in four patients (0.6%). Effectiveness was evaluated in 622 patients. LDL-C,
HDL-C, TG, and non-HDL-C levels improved significantly from baseline to LOCF by −17.4%, 8.8%, –40.5%, and
−21.6%, respectively (all, p < 0.001). Lipid levels also improved from baseline to each evaluation time-point.
Conclusions: Bezafibrate in combination with ezetimibe is safe and effective, and is potentially useful for
comprehensive management of dyslipidemia.
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Low-density lipoprotein-cholesterol (LDL-C) is one of the
most important factors for evaluating the risk associated
with cardiovascular disorders. Statins are the most com-
monly used drug for treating elevated LDL-C, and reduce
the risk of cardiovascular events, as demonstrated in large-
scale clinical trials [1].
Although statin therapy reduces the risk of cardiovascular
events by approximately 30%, the residual risk of cardiovas-
cular events is approximately 70% [2]. Therefore, it is ne-
cessary to consider additional interventions to reduce the
residual risk. In addition to LDL-C, low levels of high-
density lipoprotein-cholesterol (HDL-C) and high triglycer-
ide (TG) concentrations are considered to be risk factors
for coronary artery disease [3-5]. For this reason, it is in-
creasingly being acknowledged that integrated management
of dyslipidemia targeting LDL-C as well as HDL-C and TG
is necessary [6,7]. In particular, the European Society of
Cardiology/the European Atherosclerosis Society [8] and
the Japan Atherosclerosis Society [9] recommend fibrates
as the Class I pharmaceutical therapy for treating
hypertriglyceridemia.
Fibrates activate peroxisome proliferator-activated recep-
tor (PPAR) alpha, a nuclear receptor that affects the tran-
scriptional regulation of many genes governing lipoprotein
metabolism, thereby decreasing TG levels while increasing
HDL-C levels [10]. One of these drugs, bezafibrate, is a lig-
and for three PPAR subtypes (alpha, gamma, and delta)
and exerts unique actions that differ from those of other
fibrates [10,11]. In contrast, ezetimibe is an inhibitor of
Niemann-pick C1 like 1 protein (NPC1L1), an intestinal
cholesterol transporter that is localized to the small intes-
tinal mucosa. By inhibiting NPC1LI, ezetimibe reduces lipid
uptake from the intestine, and thereby reduces hepatic
cholesterol content and circulating LDL-C levels [12].
Because of these independent mechanisms of action, a
combination of bezafibrate and ezetimibe is expected to
provide a comprehensive treatment option for dyslipidemia
by decreasing LDL-C, increasing HDL-C, and markedly de-
creasing TG levels. In fact, several studies have already doc-
umented the efficacy of fenofibrate in combination with
ezetimibe [13-15]. In contrast, a study combining bezafibrate
and ezetimibe has not yet been conducted. For this reason,
we conducted a 12-month prospective observational study
(J-COMPATIBLE study; Japanese safety and efficacy of
long-term COMbination theraPy with bazafibrAte and eze-
TImiBe in patients with dysLipidEmia study) the safety and




This prospective observational study was conducted be-
tween January 2009 and February 2011 and involved 157medical institutions in Japan. After obtaining written in-
formed consent, a central registration system was used
to enroll patients who satisfied all eligibility criteria. This
study was conducted in accordance with Good Post-
marketing Study Practice (GPSP) of the Ministry of
Health, Labour, and Welfare, Japan. Approval by the eth-
ics committee of each institution was not mandatory,
because GPSP does not require such approval for Post-
Marketing Surveillance.
Dyslipidemic patients who received combination ther-
apy with bezafibrate and ezetimibe for the first time
were eligible for enrollment. Patients with any of the fol-
lowing were excluded: (1) gallstone, suspected gallstone,
or history of gallstone; (2) blood creatinine ≥ 2.0 mg/dL
within 1 month before starting treatment; (3) severe
renal disease (defined as on dialysis or renal failure); or
(4) severe liver disease.
Study design
Before starting the study, patients treated with 400 mg/
day bezafibrate added 10 mg/day ezetimibe to their on-
going bezafibrate regimen, or vice versa. Patients who
were naïve to both drugs began taking these two drugs
concurrently at the start of the study. The study period
was defined as that from the start of combination ther-
apy (baseline) to 12 months of treatment or until pa-
tients discontinued the regimen.
Safety was evaluated in all patients except those with
protocol violations or for whom there were insufficient
data for assessing safety. Efficacy was evaluated for all
patients except those who did not comply with drug ad-
ministration, had protocol violations, or who had insuffi-
cient data for assessing safety.
Safety assessments
We evaluated adverse drug reactions (ADRs) during com-
bination therapy with bezafibrate and ezetimibe. Patients
underwent ultrasonography at baseline and at the end of
the observation period to detect the presence of gallstones.
Safety parameters included body mass index (BMI), total
bilirubin, blood creatinine, blood urea nitrogen, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
gamma-glutamyl transpeptidase (GGT), alkaline phosphat-
ase (ALP), creatine phosphokinase (CPK), systolic blood
pressure, diastolic blood pressure, and glycated hemoglobin.
Glycated hemoglobin was measured according to the Japan
Diabetes Society method [16] and values were converted
to National Glycohemoglobin Standardization Program
values.
Efficacy assessments
Efficacy parameters were LDL-C, HDL-C, TG, and non-
HDL cholesterol (non-HDL-C). These values were mea-
sured at baseline, and after 1, 3, 6, and 12 months of
Table 1 Baseline patient characteristics (safety analysis set)
Characteristics n mean ± SD/%
Age (years) 659 60.8 ± 13.1
Men (%) 384 58.3
With complications (%) 551 83.6
Concurrent disease
Hypertension (%) 368 55.8
Diabetes (%) 230 34.9
Hepatic disease (%) 152 23.1
Cardiac disease (%) 46 7.0
Renal disease (%) 20 3.0
Purpose of combination therapy a
Primary prevention (%) 604 91.7
Secondary prevention (%) 26 3.9
Unknown (%) 29 4.4
Concomitant medications
Drugs for hypertension (%) 355 53.9
Drugs for diabetes (%) 163 24.7
Statin (%) 14 2.1
Data are expressed as mean ± standard deviation or n and percent.
aDefined according to the Guidelines for the Prevention of Atherosclerotic
Cardiovascular Disease 2007 [9].
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formula (LDL-C = total cholesterol – HDL-C – TG/5),
in patients with TG < 400 mg/dL [17]. Non-HDL-C was
calculated by subtracting HDL-C from total cholesterol
(data not shown).
Statistical analysis
All statistical analyses were performed using SAS version
9.2 (SAS Institute Inc., Cary, NC, USA). Data are shown
as means ± standard deviation (SD). The cumulative in-
cidence of ADRs was estimated using the Kaplan–Meier
method. The changes from baseline to the last observa-
tion carried forward (LOCF), or to specific time-points,
in safety and efficacy parameters were analyzed using a
two-tailed paired t-test. Furthermore, all patients were
classified into three groups according to drug adminis-
tration background at the start of the study: (1) patients
who were already taking ezetimibe and then added beza-
fibrate (EZE + BEZA group); (2) patients who were
already taking bezafibrate and then added ezetimibe
(BEZA + EZE group); and (3) patients who started beza-
fibrate and ezetimibe concurrently (BEZA & EZE group).
For inter-group comparisons of ADRs, the χ2 test was
used for statistical analysis. For lipid parameters, the dif-
ferences among the three groups were evaluated by ana-
lysis of covariance (ANCOVA), with application of the
model to the baseline value as the covariate and the
change in each efficacy variable. The statistical signifi-
cance level was set at 5%. Patients without ADRs were
included in the analysis with the day they stopped com-
bination therapy as the treatment termination point.
The LOCF method was used to impute missing data.
The necessary sample size was calculated to be ≥ 500
patients based on two studies of fenofibrate in combin-
ation with ezetimibe, in which Farnier et al. enrolled 625




Of 665 patients enrolled in the study, safety was evalu-
ated in 659 (Table 1) after excluding five patients in
whom ADRs could not be identified and one patient
who did not receive combination therapy. The mean age
± SD of the patients was 60.8 ± 13.1 years. Concurrent
diseases were observed in 83.6% of patients, and in-
cluded hypertension (55.8%), diabetes (34.9%), hepatic
disease (23.1%), cardiac disease (7.0%), and renal disease
(3.0%). In 91.7% of patients, combination therapy was
planned as a primary prevention based on the Japan
Atherosclerosis Society Guidelines [9]. Fourteen patients
(2.1%) also received statins.
Efficacy was evaluated in 622 patients, after excluding
the six patients who had been excluded from the safetyassessment, 10 who had a history of gallstones, 13 with
registration violations, and 14 who did not comply with
the drug administration regimen.Safety assessments
Of the 659 patients included in the safety analysis, 42
(6.4%) experienced ADRs (Table 2). The most common
ADRs were blood CPK increase (1.5%), myalgia (0.8%),
gallstone (0.6%), increased blood creatinine (0.6%), and
increased AST (0.5%). Severe ADRs occurred in three
patients, and included increases in both blood CPK and
blood creatinine in one patient, gastric cancer in one pa-
tient, and both bleeding stomach ulcer and gastric can-
cer in one patient. These three patients discontinued
combination therapy, and all recovered with appropriate
treatment. The cumulative incidences of ADRs were
4.0% (95% confidence interval [CI]: 2.7–5.8%), 4.8%
(95% CI: 3.4–6.8%), and 6.2% (95% CI: 4.6–8.4%) at 3, 6,
and 12 months, respectively, with no marked increase in
the incidence of ADRs over time. Of 359 patients who
underwent ultrasonography at baseline and at the com-
pletion of observation, four had asymptomatic gallstones
at the end of the observation period.
The changes in safety parameters are presented in
Table 3. Total bilirubin, AST, ALT, GGT, ALP, systolic
blood pressure, and diastolic blood pressure decreased
significantly from baseline to the LOCF, while creatinine
and blood urea nitrogen increased significantly.
Table 2 Adverse drug reactions in the safety analysis set
Adverse drug reactions n %
Patients evaluated 659 −
Patients with ADRs 42 6.4
ADRs in≥ 0.3% of patients
Blood CPK increased 10 1.5
Myalgia 5 0.8
Gallstone 4 0.6
Blood creatinine increased 4 0.6
AST increased 3 0.5
Gastric cancer 2 0.3
Diabetes 2 0.3
Renal dysfunction 2 0.3
ALT increased 2 0.3
Blood TG increased 2 0.3
ADRs: adverse drug reactions; CPK: creatine phosphokinase; AST: aspartate
aminotransferase; ALT: alanine aminotransferase; TG: triglyceride.
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Efficacy was assessed in 622 patients. The changes in
LDL-C, HDL-C, TG, and non-HDL-C from baseline to
LOCF and to each time-point are shown in Figure 1.
LDL-C decreased significantly by 17.4% from 136.2 ±
36.6 mg/dL at baseline to 112.5 ± 27.4 mg/dL at LOCF
(change: –23.7 ± 36.1 mg/dL; p < 0.001). HDL-C in-
creased by 8.8% from 52.1 ± 14.2 mg/dL to 56.7 ±
14.3 mg/dL (change: 4.6 ± 11.2 mg/dL; p < 0.001). TG
decreased by 40.5% from 266.6 ± 210.1 mg/dL to 158.6 ±
112.2 mg/dL (change: –108.0 ± 181.3 mg/dL; p < 0.001).
Non-HDL-C decreased significantly by 21.6% fromTable 3 Changes in safety parameters
Parameter n Baseline LOCF p-value
Body mass index (kg/m2) 362 25.49 ± 3.72 25.40 ± 3.77 0.087
Total bilirubin (mg/dL) 292 0.64 ± 0.25 0.58 ± 0.22 <0.001
Creatinine (mg/dL) 449 0.76 ± 0.17 0.78 ± 0.19 <0.001
Blood urea nitrogen (mg/dL) 392 15.30 ± 3.92 16.35 ± 4.84 <0.001
AST (IU/L) 479 30.8 ± 19.7 28.8 ± 15.1 0.007
ALT (IU/L) 479 31.9 ± 28.2 26.8 ± 21.3 <0.001
GGT (IU/L) 451 66.1 ± 96.1 48.4 ± 69.6 <0.001
ALP (IU/L) 309 224.1 ± 87.9 184.7 ± 67.5 <0.001
CPK (mg/dL) 301 127.8 ± 82.9 132.0 ± 95.6 0.416
SBP (mmHg) 489 130.4 ± 13.5 128.6 ± 12.4 0.002
DBP (mmHg) 486 76.0 ± 9.5 74.8 ± 8.8 0.004
HbA1c (%) 308 6.46 ± 1.41 6.39 ± 1.29 0.187
Data are expressed as mean ± standard deviation safety parameters from
baseline to LOCF. The paired t test was used to examine the significance of
within-group changes. LOCF: last observation carried forward; AST: aspartate
aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl trans-
peptidase; ALP: alkaline phosphatase; CPK: creatine phosphokinase; SBP: sys-
tolic blood pressure; DBP: diastolic blood pressure; HbA1c:
glycated hemoglobin.183.5 ± 41.8 mg/dL to 143.8 ± 32.4 mg/dL (change: –
39.6 ± 40.9 mg/dL; p < 0.001). All four parameters im-
proved significantly from baseline to each evaluation
time-point.
The subgroup analysis for drug administration
In total, 659 patients included in the safety analysis were di-
vided into three groups in terms of background characteris-
tics at baseline. Table 4 shows these baseline background
factors. Of these patients, 174 (26.4%) were in the EZE +
BEZA group, 257 (39.0%) in the BEZA+ EZE group, and
228 (34.6%) in the BEZA & EZE group. The mean ages
were 62.5 ± 12.9, 59.2 ± 12.0 and 61.2 ± 14.2 years in the
EZE + BEZA, BEZA+ EZE and BEZA & EZE groups, re-
spectively. The complications, concurrent diseases, purpose
of combination therapy and concomitant medications
showed no imbalances among these three groups. ADRs
were noted in 14 subjects (8.0%) in the EZE + BEZA group,
19 (7.4%) in the BEZA+ EZE group and 9 (3.9%) in the
BEZA & EZE group. Gallstones were noted in 2 subjects
(1.1%) in the EZE + BEZA group, 1 (0.4%) in the BEZA+
EZE group and 1 (0.4%) in the BEZA & EZE group. ADR
incidences did not differ significantly among the three
groups (P = 0.172).
For the 622 patients included in the efficacy analysis,
Table 5 shows the change and the rate of change in lipid
levels from baseline to the LOCF in each group. The
mean treatment durations were 370.5, 377.1, and
348.3 days in the EZE + BEZA, BEZA + EZE, and BEZA
& EZE groups, respectively. As in the entire patient
population, LDL-C, HDL-C, TG, and non-HDL-C values
improved between baseline and the LOCF in all three
treatment groups. Among baseline lipid parameters,
LDL-C was high in the BEZA + EZE group, TG was high
in the EZE + BEZA group, and LDL-C, TG and non-
HDL-C were high in the BEZA & EZE group.
The changes in LDL-C, HDL-C, TG and non-HDL-C
from baseline to the LOCF were compared among the
EZE + BEZA, BEZA + EZE and BEZA & EZE groups
employing an ANCOVA model. Only changes in HDL-C
and TG differed significantly among the three groups
(LDL-C: P = 0.471, HDL-C: P = 0.008, TG: P = 0.039,
non-HDL-C: P = 0.343). The adjusted change in HDL-C
from baseline (estimate ± standard error) was 5.8 ±
0.9 mg/dL in the EZE + BEZA group, 2.6 ± 0.8 mg/dL in
the BEZA + EZE group and 5.8 ± 0.9 mg/dL in the BEZA
& EZE group, and the adjusted change in TG was
−121.3 ± 8.1 mg/dL in the EZE + BEZA group, –94.4 ±
7.1 mg/dL in the BEZA + EZE group and −111.6 ±
7.7 mg/dL in the BEZA & EZE group.
Discussion
Fibrates are thought to be the most effective drugs for treat-
ing low HDL-C and high TG levels [18,19]. Bezafibrate
136.2





















Baseline 1 3 6 12
249 134 201 171 150 249
52.1










Baseline 1 3 6 12


















Baseline 1 3 6 12




























Baseline 1 3 6 12











Figure 1 Changes in LDL-C, HDL-C, TG, and non-HDL-C levels from baseline to the LOCF. Data are expressed as mean ± standard deviation.
The paired t test was used to examine the significance of within-group changes from baseline to the last observation carried forward (LOCF). ***
p < 0.001. LDL-C levels were estimated using the Friedewald formula.
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and increase HDL-C levels by 14.0% in the J-BENEFIT
study [20]. Concurrent administration of a fibrate and a sta-
tin might be a feasible treatment option for patients with
mixed dyslipidemia who also have relatively high LDL-C
levels. However, some caution is necessary because a high
risk of rhabdomyolysis was reported during concurrent use
of these drugs, especially in patients with renal dysfunction
complications [21].
Ezetimibe acts by inhibiting the enterohepatic recircu-
lation of lipids. In post-kidney transplantation patients,
ezetimibe was found to stabilize creatinine clearance and
also to suppress further decreases in renal function [22].
It differs from fibrates, which pass through the kidneys
and are excreted in urine. A meta-analysis revealed that
10 mg/day ezetimibe as monotherapy decreased LDL-C
by 18.58%, increased HDL-C by 3.00%, and decreased
TG by 8.06% [23]. Therefore, bezafibrate in combination
with ezetimibe is thought to be a feasible approach to
reducing residual cardiovascular risk because this com-
bination is expected to improve low HDL-C and high
TG levels and to decrease LDL-C levels, while providing
a good safety profile.
Fibrates reportedly increase the excretion of choles-
terol into bile and may promote gallstone formation[24]. Ezetimibe does not promote cholelithiasis, accord-
ing to one study [25]. To date, however, the risk of gall-
stones with bezafibrate in combination with ezetimibe
has not been adequately evaluated. Therefore, in this
study, we performed ultrasonography at baseline and at
the end of the observation period to detect gallstones
which had developed during combination therapy. We
also evaluated the efficacy of this combination therapy in
terms of improvements in lipid levels.
ADRs occurred in 6.4% of patients, which was similar
to the value of 5.1% reported in our previous study
(J-BENEFIT) in which bezafibrate was administered
alone [20], and to the rate of 7.0% in patients treated
with fenofibrate in combination with ezetimibe [13]. Se-
vere ADRs occurred in three patients and the adminis-
tration of these drugs was terminated in all three. None
of the patients in this study experienced rhabdomyolysis.
All four patients with gallstones (0.6%) had diabetes in
addition to dyslipidemia and were > 50 years old. Three
of these patients were obese with BMIs of 28.6, 29.6, and
30.1 kg/m2. Because dyslipidemia, diabetes, advanced
age, and obesity are known risk factors for gallstones
[26], it seems likely that these subjects had physiological
features that predisposed them to gallstone formation.
The gallstone incidence based on the study duration was
Table 4 Baseline patient characteristics (patients grouped according to treatment order)
Characteristics EZE + BEZA BEZA + EZE BEZA & EZE
n mean ± SD/% n mean ± SD/% n mean ± SD/%
Age (years) 174 62.5 ± 12.9 257 59.2 ± 12.0 228 61.2 ± 14.2
Men (%) 94 54.0 173 67.3 117 51.3
With complications (%) 152 87.4 220 85.6 179 78.5
Concurrent disease
Hypertension (%) 106 60.9 141 54.9 121 53.1
Diabetes (%) 61 35.1 100 38.9 69 30.3
Hepatic disease (%) 34 19.5 68 26.5 50 21.9
Cardiac disease (%) 8 4.6 19 7.4 19 8.3
Renal disease (%) 2 1.1 8 3.1 10 4.4
Purpose of combination therapya
Primary prevention (%) 152 87.4 245 95.3 207 90.8
Secondary prevention (%) 5 2.9 11 4.3 10 4.4
Unknown (%) 17 9.8 1 0.4 11 4.8
Concomitant medications
Drugs for hypertension (%) 104 59.8 141 54.9 110 48.2
Drugs for diabetes (%) 44 25.3 72 28.0 47 20.6
Statin (%) 3 1.7 4 1.6 7 3.1
Data are expressed as mean ± standard deviation or n and percent.
aDefined according to the Guidelines for the Prevention of Atherosclerotic Cardiovascular Disease 2007 [9]. EZE + BEZA: patients who were already taking
ezetimibe and then added bezafibrate at the start of the study; BEZA + EZE: patients who were already taking bezafibrate and then added ezetimibe at the start
of the study; BEZA & EZE: patients who started bezafibrate and ezetimibe concurrently.
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the general population was reported to be 1.4 per 100
person-years [27] or 3.56%/year in an epidemiological
study conducted in Taiwan that examined diabetic pa-
tients without gallstones [28]. Thus, the gallstone inci-
dence in this study did not differ from that in the
general population.
In terms of the impact of combination therapy on
renal function, we observed a significant increase in cre-
atinine levels between baseline and LOCF, although the
magnitude of the increase was not clinically meaningful.
However, because we did not determine the estimated
glomerular filtration rate (eGFR), further studies will be
necessary to evaluate the effects of this combination on
renal function. We also considered the impact of com-
bination therapy on liver functions. Co-administration of
fenofibrate and ezetimibe reportedly increases the risk of
hepatic dysfunction [13,15]. In our study, however, AST,
ALT, GGT, and ALP decreased significantly from base-
line to the LOCF. Bezafibrate accelerates fatty acid beta-
oxidation by stimulating PPAR alpha receptors in the
liver [29], and was reported to have lower hepatotoxicity
than fenofibrate in mitochondrial toxicity studies using
rat livers [30].
In the safety evaluation, co-administration of bezafi-
brate and ezetimibe was shown to not increase the risk
of gallstone formation. In addition, liver function testvalues decreased, and BMI, systolic blood pressure, dia-
stolic blood pressure and glycated hemoglobin levels
showed no adverse influences. On the other hand, “in-
creased blood CPK” and “myalgia” were noted as ADRs,
and creatinine and blood urea nitrogen levels were sig-
nificantly increased. As described in the exclusion cri-
teria for this study, bezafibrate should not be
administered to patients with a serum creatinine level ≥
2.0 mg/dL.
In the efficacy analysis, LDL-C, TG, and non-HDL-C
levels decreased and HDL-C increased significantly from
baseline to the LOCF during combination therapy (all,
p < 0.001). In particular, non-HDL-C levels decreased
significantly from 183.5 mg/dL at baseline to 143.8 mg/dL
at the LOCF (change: –39.6 mg/dL). This change is greater
than that in the J-BENEFIT study [17], in which
2818 patients received bezafibrate monotherapy and non-
HDL-C levels decreased from 178.3 mg/dL at baseline to
160.2 mg/dL at the LOCF (change: –18.1 mg/dL). These
observations suggest that the combination therapy used in
this study had beneficial effects on lipid profiles. The non-
HDL-C fraction contains the lipoproteins that can cause ar-
teriosclerosis, including remnant lipoproteins, and higher
non-HDL-C levels were suggested to be associated with
greater risk of coronary artery disease [31]. It was also re-
ported that non-HDL-C is a better marker than LDL-C for
estimating the risk of arteriosclerotic disease [32]. In
Table 5 Changes in lipid parameters in all patients and patients grouped according to treatment order
Parameter n Baseline LOCF Change % p-value
LDL-C
Total 249 136.2 ± 36.6 112.5 ± 27.4 −23.7 ± 36.1 −17.4 <0.001
EZE + BEZA 67 120.0 ± 31.1 110.5 ± 22.9 −9.4 ± 31.7 −7.8 0.017
BEZA + EZE 99 143.6 ± 32.4 114.6 ± 25.1 −29.1 ± 29.0 −20.3 <0.001
BEZA & EZE 83 140.6 ± 41.5 111.6 ± 33.0 −29.0 ± 43.5 −20.6 <0.001
HDL-C
Total 445 52.1 ± 14.2 56.7 ± 14.3 4.6 ± 11.2 8.8 <0.001
EZE + BEZA 138 52.5 ± 14.4 58.2 ± 14.8 5.7 ± 10.3 10.9 <0.001
BEZA + EZE 164 53.0 ± 15.2 55.4 ± 14.3 2.4 ± 12.0 4.5 0.012
BEZA & EZE 143 50.6 ± 12.6 56.9 ± 13.7 6.3 ± 10.9 12.5 <0.001
TG
Total 483 266.6 ± 210.1 158.6 ± 112.2 −108.0 ± 181.3 −40.5 <0.001
EZE + BEZA 143 274.9 ± 169.0 147.6 ± 77.8 −127.3 ± 149.7 −46.3 <0.001
BEZA + EZE 183 244.0 ± 193.0 166.0 ± 125.0 −78.0 ± 193.7 −32.0 <0.001
BEZA & EZE 157 285.4 ± 256.7 160.1 ± 122.2 −125.2 ± 189.0 −43.9 <0.001
Non-HDL-C
Total 293 183.5 ± 41.8 143.8 ± 32.4 −39.6 ± 40.9 −21.6 <0.001
EZE + BEZA 85 168.2 ± 33.2 142.7 ± 30.0 −25.5 ± 33.2 −15.2 <0.001
BEZA + EZE 112 187.3 ± 43.1 144.1 ± 29.2 −43.1 ± 39.2 −23.0 <0.001
BEZA & EZE 96 192.5 ± 43.7 144.5 ± 38.0 −48.0 ± 46.0 −24.9 <0.001
Data are expressed as mean ± standard deviation. “Change” indicates the change from baseline to the LOCF value. “%” indicates rate of change from baseline to
the LOCF. The paired t test was used to examine the significance of within-group changes. LDL-C was estimated using the Friedewald formula. LOCF: last observa-
tion carried forward; EZE + BEZA: patients who were already taking ezetimibe and then added bezafibrate at the start of the study; BEZA + EZE: patients who were
already taking bezafibrate and then added ezetimibe at the start of the study; BEZA & EZE: patients who started bezafibrate and ezetimibe concurrently.
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that, in patients with TG > 400 mg/dL, non-HDL-C should
be used rather than LDL-C as a clinical marker.
In the subgroup analysis, when the lipid parameter
changes at the LOCF from the baseline level in each of the
three groups (EZE + BEZA, BEZA+ EZE and BEZA & EZE
groups) were compared, significant improvement was seen
in all lipid parameters. In addition, comparisons among the
three groups revealed no significant differences in LDL-C
or non-HDL-C. These efficacies were similar in the three
groups and a complementary effect was seen. On the other
hand, even after adjusting for baseline values, the analysis
of covariance (ANCOVA) method showed significant dif-
ferences in HDL-C and TG. These observations might be
attributable to HDL-C and TG responding differently to
the treatment interventions.
Our study has several important limitations. First, this
was conducted as a post-marketing, prospective observa-
tional study, and was designed to examine and confirm
the safety and efficacy of bezafibrate in combination with
ezetimibe in patients with dyslipidemia, without a control
group. Because it is impossible to remove all of the poten-
tial confounding factors, our results should be interpreted
with caution until a randomized controlled study with a
large number of patients can be performed. Second, forlogistic, economic, and other reasons, laboratory parame-
ters were measured at each of the participating institu-
tions, rather than in a central laboratory. Third, LDL-C
levels were estimated using the Friedewald formula.
Therefore, cases with TG ≥ 400 mg were not evaluated for
LDL-C [17]. Fourth, the usefulness of triple combination
therapy with fenofibrate, ezetimibe and a statin has re-
cently been reported [33,34]. Since this study was con-
ducted for the purpose of clarifying the safety and efficacy
of combination therapy with bezafibrate and ezetimibe, in-
vestigation of triple combination therapy with the addition
of a statin was not part of the study design. Even in the
case of combination therapy with bezafibrate and ezeti-
mibe, an insufficient effect was seen in some patients. It is
therefore necessary to sufficiently investigate triple com-
bination therapy with the addition of a statin in future
studies.
Nevertheless, this was the first study to examine the
safety and efficacy of bezafibrate in combination with
ezetimibe, and we confirmed that this combination
achieved significant improvements in LDL-C, HDL-C,
TG, and non-HDL-C levels. From the perspective of cor-
onary artery disease prevention, this combination is use-
ful as part of comprehensive management regimen for
dyslipidemia.
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From the perspective of coronary artery disease preven-
tion, comprehensive management of dyslipidemia is ne-
cessary by treating patients with low HDL-C and/or high
TG levels in addition to those with high LDL-C levels.
Based on our results, bezafibrate in combination with
ezetimibe is a safe and effective treatment option that
achieved marked improvements in LDL-C levels to-
gether with the expected increase in HDL-C levels and a
decrease in TG levels.
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